Back to Agenda
Session 1: Global Post-Approval Changes: leveraging the experience with the COVID-19 vaccines and treatments
Session Chair(s)
Frank Montgomery, PHD
Global Head Regulatory CMC, GRAPSQA, AstraZeneca, United Kingdom
Susanne Ausborn, PHD
Global Head International Regulatory Policy, Roche, Switzerland
The COVID-19 crisis has forced regulators and industry to think differently to accelerate approval and supply of desperately needed vaccines and medicines. This session, with input from WHO and global health authorities, will look at these innovations, how they can be broadened to expand ongoing covid vaccine and therapeutics supply and discuss how we could sustain them post pandemic to help resolve the desperate problems associated with global post approval CMC changes.
Speaker(s)
Sau Lee, PHD
Deputy Super Office Director, OPQ, CDER, FDA, United States
Regulatory Approaches to Enabling Manufacturing Capacity in the COVID-19 Pandemic
Sean Barry, PHD
Senior Pharmaceutical Assessor , Health Products Regulatory Authority (HPRA), Ireland
Regulator Perspective
Connie Langer, MSC
Senior Director, Pfizer Inc, United States
Case Study: COVID-19 Vaccine Regulatory & Technical Learnings & Recommendations
Diane Wilkinson, PHD, RPH
Executive Director, Global CMC Regulatory Affairs , AstraZeneca, United Kingdom
Industry Perspective on Experiences through COVID 19 Vaccines and treatments
Mohammed H. Aldosari, PHD
Director of Biological Products Directorete, Saudi Food and Drug Authority (SFDA), Saudi Arabia
Saudi FDA experience during COVID-19
Raphael Sanches Pereira
General Manager of the Office for Medicines, ANVISA, Brazil
Panel discussion with Q&A, with the additional participation:
Have an account?